There is no specific treatment, but vaccines have been in development.
Dengvaxia® (CYD-TDV) is currently the only dengue vaccine available in the United States. Laboratory confirmation of a previous dengue infection is required for vaccination. This vaccine is recommended to prevent dengue in children aged 9–16 who have previously confirmed dengue virus infection and live in an area where dengue is common. In other countries, this vaccine may be given to individuals aged 9–45 years or 9–60 years who live in dengue-endemic areas. It is given as a 3-dose series with 6-month intervals between doses.
Qdenga® (TAK-003) is the second vaccine to be licensed. WHO recommends its use in children aged 6–16 in areas with high dengue transmission. This vaccine has a 2-dose schedule with a minimum of 3 months between doses.
